Dr. Janet Chamberlain BSc PhD FHEA
Department of Infection, Immunity & Cardiovascular Disease
University of Sheffield
Beech Hill Road
Tel: +44 (0) 114 215 9566
Fax: +44 (0) 114 271 1863
After completing an MRC-funded PhD studentship at the University of Manchester, I spent a year working as an immunohistochemist at Zeneca Pharmaceuticals, Alderley Park. I joined the University of Sheffield in 1995, and spent 3 years as a Postdoctoral Research Associate in the Department of Cardiovascular Research (with Professor David Crossman as PI). Following this, I wrote my own funding applications, although remained as a Postdoctoral Research Associate; holding several Project Grants as Principal Investigator, working closely with Professors Sheila Francis and Julian Gunn.
My research career has focused on the understanding and prevention of restenosis and atherosclerosis, using several different experimental models. My long-standing interest is in the role of interleukin-1 (IL-1) in these diseases. My current areas of research relate to the mechanisms by which IL-1 is released from endothelial cells, the role of IL-1 in the development of atherosclerosis, and the use of IL-1 antagonists to inhibit disease progression. In addition, I am currently involved in investigating the role of carbon monoxide as a possible therapeutic for restenosis and myocardial infarction, and in research to develop a miniature stenting device for use in small calibre vessels. These studies are being undertaken in collaboration with colleagues in the Departments of Infection, Immunity & Cardiovascular Disease and Chemistry at the University of Sheffield, as well as collaborations with industry.
I am currently a University Teacher (since January 2016), in the Department of Infection, Immunity & Cardiovascular Disease.
I teach on several undergraduate and postgraduate taught modules, including MBB334 Biochemical Basis of Human Disease, CDL301 Cardiovascular Pharmacology: Personalising Medicine, and the MSc in Molecular Medicine.
I am the Module Administrator for CDL301/6301 and Course Administrator for the MRes Cardiovacular Medicine:From Molecules to Man.
- Release of IL-1 from endothelial cells (Embassy of Libya).
- Development of a novel, small calibre, balloon expandable stent system (MRC, with Prof Gunn).
- The use of carbon-monoxide releasing molecules in Restenosis/atherosclerosis (BHF, with Francis/Gunn/Mann).
- The use of carbon-monoxide releasing molecules in MI (BHF with Gunn/Iqbal/Francis/Mann).
- Cholesterol crystal formation in atherosclerosis (with Francis) .
For key publications see below. For a full list of publications click here.
- Iqbal J, Chamberlain J, Francis SE & Gunn J (2016) Role of Animal Models in Coronary Stenting. Annals of Biomedical Engineering, 44(2), 453-465.
- Alfaidi M, Wilson H, Daigneault M, Burnett A, Ridger V, Chamberlain J & Francis SE (2015) Neutrophil Elastase promotes Interleukin-1β secretion from Human Coronary Endothelium. Journal of Biological Chemistry, 290, 24067-24078. View this article in WRRO
- Dénes Á, Pradillo JM, Drake C, Sharp A, Warn P, Murray KN, Rohit B, Dockrell DH, Chamberlain J, Casbolt H, Francis S, Martinecz B, Nieswandt B, Rothwell NJ & Allan SM (2014) Streptococcus pneumoniae worsens cerebral ischemia via interleukin 1 and platelet glycoprotein Ibα.. Ann Neurol, 75(5), 670-683. View this article in WRRO
- Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, Cross S, Long L, Zhao L, Morrell NW, Crossman DC, Newman CMH, Kiely DG, Francis SE & Lawrie A (2012) Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension.. J Exp Med, 209(11), 1919-1935. View this article in WRRO
- Denes A, Drake C, Stordy J, Chamberlain J, McColl BW, Gram H, Crossman D, Francis S, Allan SM & Rothwell NJ (2012) Interleukin-1 Mediates Neuroinflammatory Changes Associated With Diet-Induced Atherosclerosis. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 1(3). View this article in WRRO
- Ellam T, Wilkie M, Chamberlain J, Crossman D, Eastell R, Francis S & Chico TJA (2011) Dietary phosphate modulates atherogenesis and insulin resistance in apolipoprotein E knockout mice--brief report.. Arterioscler Thromb Vasc Biol, 31(9), 1988-1990.
- Watt V, Chamberlain J, Steiner T, Francis S & Crossman D (2011) TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice.. Atherosclerosis, 215(2), 348-354.
- Lawrie A, Hameed AG, Chamberlain J, Arnold N, Kennerley A, Hopkinson K, Pickworth J, Kiely DG, Crossman DC & Francis SE (2011) Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.. Am J Pathol, 179(4), 1693-1705. View this article in WRRO
- Chamberlain J, Wheatcroft M, Arnold N, Lupton H, Crossman DC, Gunn J & Francis S (2010) A novel mouse model of in situ stenting.. Cardiovasc Res, 85(1), 38-44. View this article in WRRO
- Evans DJW, Jackman LE, Chamberlain J, Crosdale DJ, Judge HM, Jetha K, Norman KE, Francis SE & Storey RF (2009) Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis.. Circulation, 119(1), 116-122.
- Chamberlain J, Francis S, Brookes Z, Shaw G, Graham D, Alp NJ, Dower S & Crossman DC (2009) Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding.. PLoS One, 4(4), e5073. View this article in WRRO
- Chamberlain J, Evans D, King A, Dewberry R, Dower S, Crossman D & Francis S (2006) Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice.. Am J Pathol, 168(4), 1396-1403.